NTRK Prostate Cancer in Canada: What Patients Should Know About Testing and Treatment

Prostate cancer remains one of the most commonly diagnosed cancers among Canadian men, and while most cases are driven by well-known genetic pathways, a small subset involves less familiar molecular changes. Among these is the NTRK gene fusion, a specific alteration that affects how cancer cells grow and respond to certain therapies. Though rare in prostate cancer, this alteration is increasingly relevant as precision medicine becomes more central to oncology care in Canada.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

What Is an NTRK Fusion in Prostate Cancer?

NTRK stands for neurotrophic tropomyosin receptor kinase. When a fusion occurs in one of the three NTRK genes (NTRK1, NTRK2, or NTRK3), it can create an abnormal protein that drives cancer cell growth. In prostate cancer, NTRK fusions are uncommon, appearing in a very small percentage of cases. However, their significance lies in the fact that tumours carrying this alteration may respond to a specific class of drugs called TRK inhibitors, regardless of where the cancer originated in the body. This tumour-agnostic approach to treatment is a relatively new development in oncology and is reshaping how certain cancers are classified and treated.

How Prostate Cancer Testing and Diagnosis Works

For most patients, prostate cancer testing and diagnosis begins with a PSA blood test and a physical examination, followed by imaging and a biopsy if needed. Once cancer is confirmed, further molecular testing may be recommended, particularly in cases where the disease is advanced, has spread, or has not responded to standard hormone therapies. In these scenarios, comprehensive genomic profiling can identify specific mutations or fusions, including NTRK alterations, that might inform treatment decisions. Pathology labs at major cancer centres across Canada are increasingly equipped to conduct this type of advanced testing.

NTRK Testing Explained: How It Is Done

NTRK testing is typically performed on tumour tissue obtained during a biopsy or surgical procedure. The testing uses techniques such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), or immunohistochemistry (IHC) to detect the presence of an NTRK fusion. In Canada, access to these tests may vary depending on the province and the treating institution. Some provincial cancer agencies cover genomic testing under specific clinical criteria, while in other cases, patients may need to discuss eligibility for clinical trials or expanded access programs with their oncologist. Liquid biopsy, which analyses tumour DNA circulating in the blood, is an emerging option that may also be used in certain clinical settings.

Prostate Cancer Treatment Options for NTRK-Positive Cases

When an NTRK fusion is identified, targeted therapy with TRK inhibitors such as larotrectinib or entrectinib may be considered. These medications have received approval in several countries, including Canada, for solid tumours with NTRK fusions, based on strong clinical evidence of response rates across tumour types. For patients with prostate cancer where no NTRK fusion is found, the standard range of prostate cancer treatment options continues to apply. This includes androgen deprivation therapy (ADT), chemotherapy, radiation, and newer hormonal agents such as enzalutamide or abiraterone, depending on the stage and characteristics of the cancer.

Questions to Ask at Your Oncology Appointment

Being prepared for an oncology appointment can help patients get the most relevant information for their situation. When NTRK prostate cancer Canada is part of the conversation, useful questions might include: Has my tumour been tested for NTRK fusions or other molecular alterations? Am I eligible for genomic profiling through my provincial health plan? Are there clinical trials available that I might qualify for? What are the expected benefits and side effects of any targeted therapies being considered? Asking whether a referral to a specialized cancer centre or a molecular tumour board is appropriate can also be valuable, as these multidisciplinary teams are often better positioned to evaluate complex cases.

Understanding the molecular landscape of a prostate cancer diagnosis is becoming an increasingly important part of personalized care. While NTRK fusions in prostate cancer remain uncommon, identifying them can open doors to targeted treatment pathways that would otherwise not be considered. Canadian patients are encouraged to have open conversations with their oncology team about available testing options and what the results might mean for their individual treatment plan.